The round was co-led by the Northern Powerhouse Investment Fund II and Praetura Equity Finance, with backing from Auriga and SFC Capital.
"Automated scanning technologies have transformed the way we identify and remediate most vulnerabilities. However, companies still need to rely on manual penetration testing for certain classes of vulnerability that automated tools can’t detect. This area of the market has remained largely a stagnant and annual process, meaning a proportion of vulnerabilities are left to be detected just once a year. Cytix is here to change that using the latest AI models to bring all testing forward and create targeted testing at scale."
Balderton Capital led the pre-seed round, which will fund the development of continual learning models for Proxy assistants.
"Imagine an agent that keeps growing and learning whenever you teach them something new. Over time, the agent will take on mundane tasks allowing you to focus on higher-level tasks that are more impactful and also more enjoyable. The key to our approach is the ability for Proxy to learn and memorise tasks on the job, remembering them for the long term and being able to use its memories to extrapolate to new tasks – just as a person would. Our mission at Convergence is to build new, foundationally different technologies that are a clear pathway to useful intelligence. Balderton shares our vision deeply and we are looking forward to turning it into a reality with them."
The investment round was led by Zinal Growth with participation from Index Ventures, Bessemer Venture Partners, and Tony Fadell.
"We’ve been deeply impressed by the execution and vision of Bogdan and the Apron team. They have created a delightful product for both SMBs and accountants, and we are excited to continue supporting them on their journey."
The seed round was backed by British Design Fund to support the development of novel wound care devices.
"Around the world, wounds are still being treated largely the same way as they were 150 years ago, with dressings that are often not fit for purpose, leading to a slow, painful treatment process and poor outcomes for patients."
Dig Ventures led the pre-seed financing round to support product development and international growth.
"I recall regularly sifting through data and information until the early hours during my time at Goldman Sachs in order to make fully informed decisions and strategies. With Desia the whole process would have been more efficient and successful. I wish it was available back then."
